Literature DB >> 25984449

Goal attainments and their discrepancies for low density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apo B) in over 2,000 Chinese patients with known coronary artery disease or type 2 diabetes.

Yong-Ming He1, Xiang-Jun Yang1, Xin Zhao1, Hai-Feng Xu1.   

Abstract

PURPOSE: Low density lipoprotein cholesterol (LDL-C) is primary treatment target for patients with dislipidemia. The apolipoprotein B (apo B), an emerging biomarker for cardiovascular risk prediction, appears to be superior to the LDL-C. However, little is known about goal attainments and their discrepancies for LDL-C and apo B in Chinese patients with known CAD or DM.
METHODS: A total of 2,172 hospitalized patients with known coronary artery disease (CAD) or DM, aged >27 years of old, were enrolled. The success rates for apo B and LDL-C goal attainments were evaluated and compared by categorization and by sex.
RESULTS: When the success rates for apo B were compared with the ones for LDL-C, the former was higher than the latter across all categorizations, with the statistically significant differences seen in all patients, CAD alone and DM alone (P<0.0001), but not in coexistence of CAD and DM (P=0.190). The trend toward to higher success rates for LDL-C and apo B goal attainments in men than in women were noteworthy across all categorizations although only in all patients and in DM alone patients were the statistically significant differences found (P<0.01).
CONCLUSIONS: The LDL-C lags behind the apo B in goal attainments in Chinese patients. Whether these discrepancies are associated with the occurrence differences for CAD and for stroke between the East Asia and the Western countries warrants further study.

Entities:  

Keywords:  Apolipoprotein B (apo B); coronary artery disease (CAD); diabetes mellitus (DM); goal attainments; low density lipoprotein cholesterol (LDL-C)

Year:  2015        PMID: 25984449      PMCID: PMC4420678          DOI: 10.3978/j.issn.2223-3652.2015.03.04

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  19 in total

1.  Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.

Authors:  Christie M Ballantyne; Michael A Blazing; Thomas R King; William E Brady; Joanne Palmisano
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

Review 2.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Alice Yy Cheng; Lawrence A Leiter
Journal:  Curr Opin Cardiol       Date:  2006-07       Impact factor: 2.161

3.  Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.

Authors:  S Holewijn; M den Heijer; D W Swinkels; A F H Stalenhoef; J de Graaf
Journal:  J Intern Med       Date:  2010-12       Impact factor: 8.989

4.  Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-china.

Authors:  Andrew Moran; Dongfeng Gu; Dong Zhao; Pamela Coxson; Y Claire Wang; Chung-Shiuan Chen; Jing Liu; Jun Cheng; Kirsten Bibbins-Domingo; Yu-Ming Shen; Jiang He; Lee Goldman
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-05-04

5.  Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.

Authors:  David D Waters; John C LaRosa; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Roddy Carter; Andrei Breazna; John J P Kastelein; Scott M Grundy
Journal:  J Am Coll Cardiol       Date:  2006-10-17       Impact factor: 24.094

6.  Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.

Authors:  Jong-Seon Park; Young-Jo Kim; Ji-Yong Choi; Yoon-Nyun Kim; Teck-Jong Hong; Dong-Soo Kim; Ki-Young Kim; Myung-Ho Jeong; Jei-Keon Chae; Seok-Kyu Oh; In-Whan Seong
Journal:  Korean J Intern Med       Date:  2010-02-26       Impact factor: 2.884

7.  Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).

Authors:  Jennifer G Robinson; Christie M Ballantyne; Scott M Grundy; Willa A Hsueh; Hans-Henrik Parving; Jeffrey B Rosen; Adeniyi J Adewale; Adam B Polis; Joanne E Tomassini; Andrew M Tershakovec
Journal:  Am J Cardiol       Date:  2009-06-15       Impact factor: 2.778

8.  Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese.

Authors:  Kuo-Liong Chien; Hsiu-Ching Hsu; Ta-Chen Su; Ming-Fong Chen; Yuan-Teh Lee; Frank B Hu
Journal:  J Lipid Res       Date:  2007-08-13       Impact factor: 5.922

9.  Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.

Authors:  Beth L Abramson; Pascale Benlian; Mary E Hanson; Jianxin Lin; Arvind Shah; Andrew M Tershakovec
Journal:  Lipids Health Dis       Date:  2011-08-22       Impact factor: 3.876

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.